These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2097710)

  • 1. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
    Schentag JJ
    Scand J Infect Dis Suppl; 1990; 74():218-34. PubMed ID: 2097710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection.
    Frimodt-Møller N
    Dan Med Bull; 1988 Oct; 35(5):422-37. PubMed ID: 3066588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
    Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.
    Drusano GL
    Scand J Infect Dis Suppl; 1990; 74():235-48. PubMed ID: 2097712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.
    Goss TF; Forrest A; Nix DE; Ballow CH; Birmingham MC; Cumbo TJ; Schentag JJ
    Ann Pharmacother; 1994; 28(7-8):863-8. PubMed ID: 7949501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and in vitro activity of the ciprofloxacin-azlocillin combination (ratio 1:10) against gram-negative bacteria from non-neutropenic haematologic patients.
    Piccolomini R; Di Girolamo A; Iacone A; Fioritoni G; Cellini L; Nicoletti M; D'Antonio D
    Drugs Exp Clin Res; 1991; 17(9):455-60. PubMed ID: 1822439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the dose matter?
    Craig WA
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S233-7. PubMed ID: 11524724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
    Scaglione F; Esposito S; Leone S; Lucini V; Pannacci M; Ma L; Drusano GL
    Eur Respir J; 2009 Aug; 34(2):394-400. PubMed ID: 19213786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
    Saengsuwan P; Jaruratanasirikul S; Jullangkoon M; Aeinlang N
    J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens.
    Schaper KJ; Schubert S; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():3-14. PubMed ID: 16518706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
    Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
    Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
    Jones RN; Fritsche TR; Ge Y; Kaniga K; Sader HS
    J Antimicrob Chemother; 2005 Dec; 56(6):1047-52. PubMed ID: 16239290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How and why aztreonam works.
    Rittenbury MS
    Surg Gynecol Obstet; 1990; 171 Suppl():19-23. PubMed ID: 2244291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.